慢性乙型肝炎患者血清HBV-DNA病毒载量与血清肝纤维化指标变化  

Relationship Between Changes of Blood HBV-DNA Viral Load and Serum Liver Fibrosis Markers (HA,LN,Ⅳ-C,PCⅢ) Levels in Patients with Chronic Hepatitis B

作　　者：王远驰[1] 黄金伟[1] 

机构地区：[1]浙江省丽水市中心医院,323000

出　　处：《放射免疫学杂志》2009年第3期222-224,共3页Journal of Radioimmanology

摘　　要：目的:探讨慢性乙型肝炎患者血清HBV-DNA病毒载量与血清肝纤维化指标变化的关系。方法:以慢性乙型病毒性肝炎患者20例为对象,分为应用抗病毒药有效抑制组10例与未进行抗病毒药治疗组10例,跟踪调查治疗情况5年(2002～2007年),用荧光定量聚合酶链反应(FQ-PCR)检测HBV-DNA病毒载量,采用放射免疫分析对20例慢性乙肝患者检查血清肝纤维化指标透明质酸(HA)、层黏蛋白(LN)、Ⅳ型胶原(Ⅳ-C)、Ⅲ型前胶原(PCⅢ)水平。结果:5年来,抗病毒药有效抑制组10例患者平均HBV-DNA病毒载量对数水平3.56±1.12,未进行抗病毒药治疗组10例平均HBV-DNA病毒载量对数水平7.76±1.23,有显著差异(P<0.05)。2002年抗病毒药有效抑制组血清肝纤维化指标分别为HA(82.72±30.62)μg/ml、LN(71.18±26.71)μg/ml、Ⅳ-C(93.77±69.87)μg/ml、PCⅢ(91.4±18.64)μg/ml,2002年未进行抗病毒药治疗组血清肝纤维化指标分别为HA(79.32±31.34)μg/ml、LN(70.25±28.23)μg/ml、Ⅳ-C(90.35±67.81)μg/ml、PCⅢ(85.77±20.56)μg/ml,两组间各项指标统计学无显著差异(P>0.05)。2007年抗病毒药有效抑制组血清肝纤维化指标分别为HA(85.72±29.52)μg/ml、LN(70.18±25.4)μg/ml、Ⅳ-C(94.2±70.92)μg/ml、PCⅢ(93.4±19.32)μg/ml,2007年未进行抗病毒药治疗组血清肝纤维化指标分别为HA(105.67±28.54)μg/ml、LN(97.75±26.25)μg/ml、Ⅳ-C(132±72.13)μg/ml、PCⅢ(120.72±19.87)μg/ml,两组间各项指标比较均有显著差异(P<0.05)。结论:有效控制慢性乙肝患者HBV-DNA病毒载量可能是控制患者肝纤维化进展的重要因素。Objective To investigate the relationship between changes of blood HBV DNA viral load and serum liver fibrosis markers levels in patients with chronic hepatitis B. Methods In 2002, 20 patients with hepatitis B were divided into two groups： Group A treated with antiviral ageat （n = 10）, Group B not treated. Five years later （2007） the blood viral load （with FQ -PCR） and serum levels of hepatic fibrosis markers （with RIA） were determined in these patients. Results The average log viral load in serum in the tow groups were 3.56±1.12 （treated group） and 7.76±1.23 respectively with significant difference （ P 〈 0.05）. In 2002, serum liver fibrosis markers （ HA, LN, Ⅳ - C, PC Ⅲ ） levels were about the same in the two groups were （ 82.72±30. 62μg/ml, 71.18± 26.71μg/ml, 93.77±69.87μg/ml, 91.4±18. 64μg/ml and 79.32±31. 34μg/ml, 70.25±28.23）μg/ml, 90.35±67.81 μg/ml, 85.77±20.56μg/ml respectively）. In 2007, in the treated patients, serum liver fibrosis markers HA, LN, Ⅳ - C, PCⅢ levels were 85.72±29.52μg/ml, 70.18±25.4μg/ml, 94.2±70.92μg/ml, 93.4±19. 32μg/ml respectively However, in the non-treated groups, the serum HA, LN, Ⅳ -C, PCⅢ levels were105.67±28. 54μg/ml, 97.75±26.25μml, 132±72. 13μml, 120.72±19.87μg/ml, being significantly higher than those in the treated group （P 〈 0.05）. Conclusion Effective decrease of the viral load might control the progress of hepatic fibrosis in patients with chronic hepatitis B.

关 键 词：慢性乙型肝炎 HBV-DNA 病毒载量 肝纤维化 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]